Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Im-Il Na"'
Autor:
Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung-Sook Lee, Sung Hyun Yang, Im Il Na, Hyo-Rak Lee, Dong-Yeop Shin, Hye Jin Kang
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 17 (2023)
Background: Radioimmunotherapy (RIT) is a rare treatment option for relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). We investigated the safety and efficacy of 131 I-rituximab in patients with relapsed or refractory marginal zone lymphom
Externí odkaz:
https://doaj.org/article/87867d920217437ca93a712ec9b5dada
Publikováno v:
Journal of Hospice & Palliative Care. Dec2023, Vol. 26 Issue 4, p171-184. 14p.
Autor:
Seo Yun Kim, M.D., Jae Kyung Myung, M.D., Hye-Ryoun Kim, M.D., Im Il Na, M.D., Ph.D., Jae Soo Koh, M.D., Ph.D., Hee Jong Baek, M.D., Ph.D., Cheol Hyeon Kim, M.D., Ph.D.
Publikováno v:
Tuberculosis and Respiratory Diseases, Vol 82, Iss 1, Pp 62-70 (2019)
Background Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers have emerged as key predictive biomarkers in EGFR tyrosine kinase inhibitor (TKI) treatment. However, a few patients with wild-type EGFR also respond to EGFR
Externí odkaz:
https://doaj.org/article/1c41828b866545c4b7f3fb575c38a2a0
Autor:
Seo Yun Kim, Hye-Ryoun Kim, Cheol Hyeon Kim, Jae Soo Koh, Hee Jong Baek, Chang-Min Choi, Joon Seon Song, Jae Cheol Lee, Im Il Na
Publikováno v:
Annals of Thoracic Medicine, Vol 12, Iss 1, Pp 36-41 (2017)
BACKGROUND: The aim of this study was to investigate the association between epidermal growth factor receptor (EGFR) mutation and thyroid cancer in female patients with nonsmall-cell lung cancer (NSCLC). METHODS: In a retrospective study, we examine
Externí odkaz:
https://doaj.org/article/4dbca0b5082445f0b85f5e5cf1260ece
Autor:
Jae Cheol Lee, Young Do Yoo, Cheol Hyeon Kim, Seung Sook Lee, Sung Hyun Yang, Im Il Na, Baek-Yeol Ryoo, Jin Kyung Lee, Yun Jung Choi, Jin Kyung Rho
Supplementary Data from The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c1bfe6cb8a238e3714cd2bd90b16b9e
https://doi.org/10.1158/1541-7786.22521657
https://doi.org/10.1158/1541-7786.22521657
Autor:
Jae Cheol Lee, Young Do Yoo, Cheol Hyeon Kim, Seung Sook Lee, Sung Hyun Yang, Im Il Na, Baek-Yeol Ryoo, Jin Kyung Lee, Yun Jung Choi, Jin Kyung Rho
The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs. MET amplification was recently found to be a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10b33092749f4c6458d9400aac523bcb
https://doi.org/10.1158/1541-7786.c.6543099.v1
https://doi.org/10.1158/1541-7786.c.6543099.v1
Autor:
Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung‐Sook Lee, Cheolwon Suh, Dok Hyun Yoon, Inho Kim, Seung‐Hyun Nam, Mark Hong Lee, Jong Ho Won, Jee Hyun Kong, Seong Hyun Jeong, Suk Joong Oh, Keon Woo Park, Jae Joon Han, Moo‐Kon Song, Sung Hyun Yang, Im Il Na, Hyo‐Rak Lee, Dong‐Yeop Shin, Hye Jin Kang
Publikováno v:
Asia-Pacific Journal of Clinical Oncology.
Publikováno v:
Journal of Hospice & Palliative Care. 2021, Vol. 24 Issue 3, p184-193. 10p.
Autor:
Seo Yun Kim, Hyo-Rak Lee, Cheol Hyeon Kim, Hye Jin Kang, Hyesil Seol, Yoon Jung Jang, Sung Hyun Yang, Hong Kyu Jung, Hye-Ryoun Kim, Im Il Na
Publikováno v:
Translational Cancer Research
Background The incidence of second primary lung cancer (SPLC) is increasing with longer survival rates from breast cancer. Despite of studies to suggest the mutual exclusivity of epidermal growth factor receptor (EGFR) and human epidermal growth rece
Publikováno v:
The Korean Journal of Hospice and Palliative Care. 24:184-193